{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:12:42Z","timestamp":1778659962256,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-44980-w","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T07:52:06Z","timestamp":1774511526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study"],"prefix":"10.1038","volume":"16","author":[{"given":"Ahmet","family":"Oru\u00e7","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130lknur","family":"Delikta\u015f Onur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galip Can","family":"Uyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taha Koray","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salih","family":"T\u00fcnbekici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ay\u015fe","family":"Arslan Kapuci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ece","family":"Ulukal Karanc\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih","family":"Kemik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015eafak","family":"Y\u0131ld\u0131r\u0131m Di\u015fli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6zt\u00fcrk","family":"Ate\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00f6k\u015fen","family":"\u0130nan\u00e7 \u0130mamo\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sercan","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burcu","family":"\u00c7akar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuriye","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Banu","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih","family":"Sel\u00e7ukbiricik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Zahid","family":"Ko\u00e7ak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melek","family":"Karakurt Ery\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Araz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Arta\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"issue":"10286","key":"44980_CR1","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","volume":"397","author":"S Loibl","year":"2021","unstructured":"Loibl, S., Poortmans, P., Morrow, M., Denkert, C. & Curigliano, G. Breast cancer. Lancet 397(10286), 1750\u20131769 (2021).","journal-title":"Lancet"},{"issue":"3","key":"44980_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks, A. G. & Winer, E. P. Breast cancer treatment: A review. JAMA 321(3), 288\u2013300 (2019).","journal-title":"JAMA"},{"issue":"10","key":"44980_CR3","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi, G. N. et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N. Engl. J. Med. 386(10), 942\u2013950 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"44980_CR4","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","volume":"35","author":"MP Goetz","year":"2024","unstructured":"Goetz, M. P. et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. Ann. Oncol. 35(8), 718\u2013727 (2024).","journal-title":"Ann. Oncol."},{"issue":"9","key":"44980_CR5","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/JCO.23.00137","volume":"42","author":"DJ Slamon","year":"2024","unstructured":"Slamon, D. J. et al. Overall survival with palbociclib plus letrozole in advanced breast cancer. J. Clin. Oncol. 42(9), 994\u20131000 (2024).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"44980_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/14737140.2021.1852934","volume":"21","author":"CE Onesti","year":"2021","unstructured":"Onesti, C. E. & Jerusalem, G. CDK4\/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. Expert Rev. Anticancer Ther. 21(3), 283\u2013298 (2021).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"44980_CR7","doi-asserted-by":"publisher","first-page":"102956","DOI":"10.1016\/j.ctrv.2025.102956","volume":"137","author":"TK Sahin","year":"2025","unstructured":"Sahin, T. K., Kavgaci, G., Guven, D. C. & Aksoy, S. Drug-Drug interactions and special considerations in breast cancer patients treated with CDK4\/6 inhibitors: A comprehensive review. Cancer Treat Rev. 137, 102956 (2025).","journal-title":"Cancer Treat Rev."},{"key":"44980_CR8","doi-asserted-by":"publisher","first-page":"103950","DOI":"10.1016\/j.clon.2025.103950","volume":"48","author":"F Petrelli","year":"2025","unstructured":"Petrelli, F., Ghidini, A. & Dottorini, L. Association between dose reduction of cyclin-dependent kinase 4\/6 inhibitors and survival in advanced breast cancer: A systematic review and meta-analysis. Clin Oncol (R Coll Radiol). 48, 103950 (2025).","journal-title":"Clin Oncol (R Coll Radiol)."},{"issue":"1","key":"44980_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s44276-024-00108-z","volume":"2","author":"A Bjerrum","year":"2024","unstructured":"Bjerrum, A. et al. Overall survival after CDK4\/6 inhibitor dose reduction in women with metastatic breast cancer. BJC Rep. 2(1), 82 (2024).","journal-title":"BJC Rep."},{"key":"44980_CR10","doi-asserted-by":"publisher","first-page":"103875","DOI":"10.1016\/j.breast.2025.103875","volume":"79","author":"P Zagami","year":"2025","unstructured":"Zagami, P. et al. Advancing treatment choices: CDK4\/6 inhibitor switching in HR+\/HER2- metastatic breast cancer. Breast 79, 103875 (2025).","journal-title":"Breast"},{"issue":"7","key":"44980_CR11","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi, G. N. et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann. Oncol. 29(7), 1541\u20131547 (2018).","journal-title":"Ann. Oncol."},{"issue":"24","key":"44980_CR12","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon, D. J. et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J. Clin. Oncol. 36(24), 2465\u20132472 (2018).","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"44980_CR13","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy, D. et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 19(7), 904\u2013915 (2018).","journal-title":"Lancet Oncol."},{"issue":"20","key":"44980_CR14","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 375(20), 1925\u20131936 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"44980_CR15","first-page":"588","volume":"33","author":"WHF Wong","year":"2025","unstructured":"Wong, W. H. F., Vasiliu, S. & McFarlane, T. Hepatotoxicity across CDK 4\/6 inhibitors: A narrative review. Support Care Cancer. 33(7), 588 (2025).","journal-title":"Support Care Cancer."},{"issue":"2","key":"44980_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/tbj.13532","volume":"26","author":"L Meynard","year":"2020","unstructured":"Meynard, L. & Grellety, T. CDK 4\/6 inhibitor successful rechallenge after limiting hepatic toxicity. Breast J. 26(2), 255\u2013257 (2020).","journal-title":"Breast J."},{"issue":"7","key":"44980_CR17","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1177\/10781552251340613","volume":"31","author":"K Jackson","year":"2025","unstructured":"Jackson, K., Roubal, K., Rangel, C. & Brescia, F. Rechallenge of an alternative CDK 4\/6 inhibitor after hepatotoxicity in the treatment of hormone-positive metastatic breast cancer. J. Oncol. Pharm. Pract. 31(7), 1174\u20131178 (2025).","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"2","key":"44980_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40257-021-00645-0","volume":"23","author":"E Raschi","year":"2022","unstructured":"Raschi, E. et al. Skin toxicities with cyclin-dependent kinase 4\/6 inhibitors in breast cancer: Signals from DISPROPORTIONALITY ANALYSIS of the FDA adverse event reporting system. Am. J. Clin. Dermatol. 23(2), 247\u2013255 (2022).","journal-title":"Am. J. Clin. Dermatol."},{"issue":"3","key":"44980_CR19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.annder.2022.11.013","volume":"150","author":"V Sibaud","year":"2023","unstructured":"Sibaud, V. & Sollena, P. Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice. Ann. Dermatol. Venereol. 150(3), 208\u2013212 (2023).","journal-title":"Ann. Dermatol. Venereol."},{"issue":"8","key":"44980_CR20","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1080\/14737140.2017.1347506","volume":"17","author":"J Ettl","year":"2017","unstructured":"Ettl, J. & Harbeck, N. The safety and efficacy of palbociclib in the treatment of metastatic breast cancer. Expert Rev. Anticancer Ther. 17(8), 661\u2013668 (2017).","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"3","key":"44980_CR21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/cpt.1950","volume":"108","author":"TS Samant","year":"2020","unstructured":"Samant, T. S. et al. Ribociclib drug-drug interactions: Clinical evaluations and physiologically-based pharmacokinetic modeling to guide drug labeling. Clin. Pharmacol. Ther. 108(3), 575\u2013585 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"44980_CR22","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/cpt.2455","volume":"111","author":"L Molenaar-Kuijsten","year":"2022","unstructured":"Molenaar-Kuijsten, L. et al. Effects of the moderate CYP3A4 inhibitor erythromycin on the pharmacokinetics of palbociclib: A randomized crossover trial in patients with breast cancer. Clin Pharmacol Ther. 111(2), 477\u2013484 (2022).","journal-title":"Clin Pharmacol Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44980-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44980-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44980-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:47:22Z","timestamp":1778658442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44980-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["44980"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-44980-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The principles of the Helsinki Declaration were adhered to during the conduct of this study. Approval for the study was granted by the Ethics Committee of Necmettin Erbakan University on 28 Nov 2025 (No: 2025\/6140). Due to the retrospective nature of the study, the Necmettin Erbakan University Ethics Committee waived the need for informed consent (2025\/6140).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The informed consent was waived due to the retrospective nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"15027"}}